Research & Development
Acurx receives FDA guidance supporting ibezapolstat Phase 3 development strategy
3 August 2026 - Biopharmaceutical company Acurx Pharmaceuticals Inc (NASDAQ: ACXP) reported on Monday that it has received further FDA guidance on its ibezapolstat clinical development programme, incl...
Zai Lab's zoci receives FDA orphan designation for neuroendocrine carcinomas
3 August 2026 - Zai Lab Limited (NASDAQ:ZLAB) (HKEX:9688), a research-based, commercial-stage biopharmaceutical company based in China and the United States, announced on Monday that the US Food and D...
Biocon launches Yesafili biosimilar in US ophthalmology market
3 August 2026 - Biopharmaceutical company Biocon Limited (BSE:532523) (NSE:BIOCON) announced on Monday the US commercial launch of Yesafili (aflibercept-jbvf), an FDA-approved interchangeable biosimil...
Ractigen Therapeutics IND application for RAG-1C receives FDA clearance
3 August 2026 - Ractigen Therapeutics, a clinical-stage biopharmaceutical company focused on small activating RNA (saRNA) therapeutics, announced on Friday that the US Food and Drug Administration (FD...
Pfizer reports positive Phase 3 results for LITFULO in nonsegmental vitiligo
30 July 2026 - US biopharmaceutical company Pfizer Inc (NYSE:PFE) on Thursday announced positive topline results from two Phase 3 trials evaluating LITFULO (ritlecitinib) as a potential oral systemic ...
European Commission approves RINVOQ for severe alopecia areata
29 July 2026 - US biopharmaceutical company AbbVie (NYSE: ABBV) said on Wednesday it has received European Commission approval for RINVOQ (upadacitinib) to treat adults and adolescents aged 12 and ove...